24/7 Market News Snapshot 11 September, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

September 11, 2025

DENVER, Colo., 11 September, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. (Ticker: MAIA), which focuses on innovative targeted immunotherapies for cancer, has shown remarkable performance in both its stock trading and clinical trial developments. Opening today at $1.64, MAIA’s stock has risen to $1.735, reflecting an impressive 11.22% increase from the previous session’s close of $1.560. This bullish movement is further supported by heightened investor interest, as evidenced by a trading volume of 2.12 million shares. Monitoring critical support levels around $1.64 and resistance at $1.80 will be vital for stakeholders looking to gauge forthcoming price movements.

In parallel, MAIA Biotechnology has announced promising outcomes from its Phase 2 clinical trial, THIO-101, which evaluates the investigational agent ateganosine (THIO) in combination with the immune checkpoint inhibitor cemiplimab (Libtayo®) for patients with advanced non-small cell lung cancer (NSCLC). Preliminary results indicate an estimated median progression-free survival (PFS) of 5.6 months for patients receiving a 180 mg dose of ateganosine, significantly higher than the 2.5 months typical of current therapies. Moreover, the median overall survival (OS) has been observed at 17.8 months, underlining the treatment’s potential effectiveness and durability.

Dr. Vlad Vitoc, Chairman and CEO of MAIA Biotechnology, emphasized the significance of these findings, stating, “THIO-101 continues to demonstrate impressive efficacy, with a progression-free survival rate that more than doubles the standard of care.” As the trial progresses into a Phase 2 expansion initiated in July 2025, MAIA aims to validate these encouraging results further. Ateganosine’s innovative mechanism, which induces selective cancer cell death while activating immune responses, positions it as a transformative prospect in NSCLC treatment, reinforcing MAIA’s commitment to advancing effective cancer therapies.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.